Thelansis’s “Pancreatic Ductal Adenocarcinoma (PDAC) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities.
Pancreatic Ductal Adenocarcinoma (PDAC) is the most prevalent and lethal form of pancreatic cancer, characterized by originating in the exocrine duct cells and having an exceptionally poor prognosis due to its typically asymptomatic early stages and late diagnosis in locally advanced or metastatic phases. Biologically, PDAC is driven by near-universal mutations in the KRAS oncogene, coupled with frequent inactivation of tumor suppressors like CDKN2A, TP53, and SMAD4. A hallmark challenge is the extensive, dense, and immune-suppressive desmoplastic tumor microenvironment (TME) that creates a physical barrier limiting drug delivery. Diagnosis relies on imaging and biopsy to confirm the cancer and determine staging, which dictates treatment strategy. While surgical resection (e.g., the Whipple procedure) offers the only chance for cure in the minority of eligible patients, the backbone of systemic treatment involves potent chemotherapy regimens like FOLFIRINOX, with targeted therapies limited to rare subsets, such as PARP inhibitors for patients with BRCA mutations.
G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven by surveys* and interviews with payers (e.g., pharmacy directors / medical directors from managed care organizations with Medicare and/or Commercial plans in the United States). If required, primary market research with physicians is also done to understand the impact of reimbursement environment on treatment decisions for current and emerging brands.
*Survey and interview discussion guide are customized based on client requirements
*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.
1. Key Findings and Analyst Commentary
2. Disease Context
3. Epidemiology
4. Market Size and Forecast
5. Competitive Landscape
6. Unmet Need and TPP Analysis
7. Regulatory and Reimbursement Environments (by country and payer insights)
8. Appendix (e.g., bibliography, methodology)
No snapshots available.
That depends on the file type you choose: the Excel epidemiology model, the Excel market forecast model with dashboard, and the full analyst report in PowerPoint with a PDF version.
Within 48 to 72 hours of purchase.
Yes. Choose EU5, G7 or G8, or pick individual markets in the panel.
Yes. Request a free sample to preview the scope and sample pages.
Yes. The forecast model is customizable, and our analysts can tailor the scope to your questions.
Yes. Inquire for bundle discounted pricing and we will send you exclusive pricing for the reports you need.
Choose the file type you want to purchase or request.
No file type found.
Select markets to include.
No markets match your search.
Not sure which report fits your question? Our team will point you to the right one.
Tell us what you are looking for and we will tailor the research to your indication, markets and questions.
Prefer to talk it through? Email clientsupport@thelansis.com
You asked for for covering . We will reply to .
Fill in your details and our expert consultants will get in touch with you.
Get a sneak peek at the latest Pancreatic Ductal Adenocarcinoma (PDAC) – Market Access and Reimbursement Insights Report – 2025 report
Our team will get in touch with you shortly about the Pancreatic Ductal Adenocarcinoma (PDAC) – Market Access and Reimbursement Insights Report – 2025 report.